Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer
- PMID: 7348575
- DOI: 10.1007/BF01806265
Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer
Abstract
Kinetic and estrogen receptor (ER) determinations were performed on 357 primary breast cancers. The proliferative activity of the cell population was determined by the autoradiographic technique and expressed as [3H]thymidine labeling index (LI): the ER status was assessed by the absorption charcoal technique. From the overall analysis of the relationship between proliferative activity and ER status, by using the median LI value as cutoff of low and high proliferating tumors, a correlation between ER + status and low proliferative activity and between ER- status and high proliferative activity was observed in 64% of the cases. Menopausal status proved to be an important determinant of kinetic and ER features. In fact, the proliferative activity was always higher in ER--tumors than in ER + tumors within the same menopausal group, and a decrease in proliferative activity was observed from premenopause to postmenopause within ER + and ER--tumors. The analysis of the relation between ER levels and proliferative activity in ER + tumors also evidenced three main ER/LI clusters significantly related to premenopause, paramenopause and postmenopause. A particular indication of nodal involvement was evidenced for a cluster of tumors with low ER levels and high LI from postmenopausal patients. The three different, previously proposed kinetic groups of potential relevance for prognostic and therapeutic purposes were confirmed and more precisely defined by considering not only premenopause and postmenopause but also paramenopause.
Similar articles
-
Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.Cancer Res. 1990 May 15;50(10):2958-62. Cancer Res. 1990. PMID: 2334898
-
Relationship between proliferative activity and estrogen receptors in breast cancer.Cancer. 1979 Aug;44(2):665-70. doi: 10.1002/1097-0142(197908)44:2<665::aid-cncr2820440237>3.0.co;2-n. Cancer. 1979. PMID: 476575
-
Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.Cancer Res. 1979 May;39(5):1447-54. Cancer Res. 1979. PMID: 427788
-
Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance.Acta Oncol. 1988;27(1):1-19. doi: 10.3109/02841868809090312. Acta Oncol. 1988. PMID: 3284552 Review.
-
Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.Breast Cancer Res Treat. 2010 Oct;123(3):641-9. doi: 10.1007/s10549-010-1116-4. Epub 2010 Aug 15. Breast Cancer Res Treat. 2010. PMID: 20711809 Review.
Cited by
-
Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer.Breast Cancer Res Treat. 1986;7(3):161-9. doi: 10.1007/BF01806246. Breast Cancer Res Treat. 1986. PMID: 3779114
-
Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer.Breast Cancer Res Treat. 1988 Apr;11(1):31-6. doi: 10.1007/BF01807555. Breast Cancer Res Treat. 1988. PMID: 3382761
-
Transferrin receptor is inversely correlated with estrogen receptor in breast cancer.Breast Cancer Res Treat. 1986;7(2):71-6. doi: 10.1007/BF01806791. Breast Cancer Res Treat. 1986. PMID: 3013349
-
3H-thymidine labeling index, hormone receptors, and ploidy in breast cancers from elderly patients.Breast Cancer Res Treat. 1991 Dec;20(1):19-24. doi: 10.1007/BF01833353. Breast Cancer Res Treat. 1991. PMID: 1813066
-
Androgen receptor expression in male breast carcinoma: lack of clinicopathological association.Br J Cancer. 1999 Feb;79(5-6):959-64. doi: 10.1038/sj.bjc.6690153. Br J Cancer. 1999. PMID: 10070897 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical